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Abstract
Background: Parthenolide, a major sesquiterpene lactone present in extracts of the herb
Feverfew, has been investigated for its inhibitory effects on mediators of inflammation, including the
proinflammatory cytokines. Although parthenolide's anti-inflammatory effects have been
investigated in vitro, little in vivo data are available. Moreover, the molecular mechanisms for these
inhibitory effects are not fully understood. The objective of this study was to test the hypothesis
that parthenolide suppresses lipopolysaccharide (LPS)-induced serum (interleukin) IL-6, tumor
necrosis factor (TNF)-α, IL-1β and cyclooxygenase (COX)-2 expression in mice as indicated by
reduced splenic and liver mRNA levels.
Methods: Mice were co-treated i.p. with LPS (1 mg/kg bw) and parthenolide (5 mg/kg bw) and
blood, spleen and liver collected. Serum was analyzed for IL-6, TNF-α and IL-1β by ELISA. Total
RNA was extracted from spleen and liver, and real-time RT-PCR was used to determine relative
mRNA expression of IL-1β, IL-6, TNF-α and COX-2.
Results: LPS induced increases in serum IL-6 and TNF-α concentrations with only IL-6 being
suppressed in parthenolide-treated mice. Induction of IL-6 mRNA was reduced, TNF-α and COX-
2 mRNAs unchanged, and IL-1β mRNA increased in spleens of parthenolide plus LPS co-treated
animals compared to LPS-only. No significant differences were observed in inflammatory gene
expression between these two groups in liver samples. Overall, mRNA expression of each
proinflammatory gene was much higher in spleen when compared to liver.
Conclusion: In summary, only one gene, IL-6, was modestly suppressed by parthenolide co-
exposure which contrasts with many in vitro studies suggesting anti-inflammatory effects of this
compound. Also, LPS evoked greater effects in spleen than liver on expression of proinflammatory
genes. Further study of the effects of parthenolide and other herbal constituents on inflammatory
gene expression using model animal systems as described here are critical to evaluating efficacy of
such supplements as well as elucidating their mechanisms of action.
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Parthenolide, the major sesquiterpene lactone derived
from the feverfew extract (Tanacetum parthenium), has
been studied for its inhibitory effects on inflammation in
cell culture and, to a limited extent, in live animals. This
constituent has been shown to attenuate a variety of
inflammatory endpoints [1-12]. Recent attention has
turned to the determination of the molecular mechanisms
by which parthenolide imparts its effects on inflammatory
responses.
Investigations of the anti-inflammatory properties of par-
thenolide, and feverfew have focused on suppression of
primary inflammatory endpoints such as platelet aggrega-
tion [1] and carrageenan-induced mouse [2] and rat [3]
paw edema. Additional studies have evaluated partheno-
lide's inhibitory effect on inflammatory mediators includ-
ing activity and expression of cyclooxygenase (COX)
[4,5], generation of prostaglandins [6,7], and leukotrienes
(LT) [4] and expression of proinflammatory cytokines
[5,8]. Most recently, the compound was found to inhibit
activation of transcription factor nuclear factor (NF)-κB
[9-12].
Previous research in our laboratory focused on the inhib-
itory effects of parthenolide on lipopolysaccharide (LPS)-
induced proinflammatory cytokine production in the
supernatant of murine cell culture and sera of animals
[13]. The data showed that parthenolide impairs LPS-
induced tumor necrosis factor (TNF)-α and interleukin
(IL)-6 upregulation in culture and in sera of animals when
parthenolide was administered via i.p. injection.
Although protein levels of LPS-induced proinflammatory
cytokines are reportedly reduced by parthenolide treat-
ment, there are limited data evaluating the effect of par-
thenolide on mRNA expression of these cytokines. Hwang
et al. [5] showed that parthenolide suppresses LPS-
induced steady state levels of TNF-α and IL-1β mRNA in
cell culture. Parthenolide had no inhibitory effect on IL-6
mRNA levels in LPS-stimulated macrophages, but did
attenuate IL-12 p40 and p35 mRNA expression [14] as
well as the chemokine IL-8 in cultured human respiratory
epithelium [15].
Parthenolide's effects on specific cytokine gene expression
have been documented in vitro, but, to our knowledge,
few data are available regarding effects on mRNA expres-
sion of cytokines or other inflammatory genes such as
COX-2 in vivo. This is an important consideration
because absorption, distribution and metabolism of this
compound will likely impact how it affects inflammation
in the host. The objective of this study was to test the
hypothesis that parthenolide-induced suppression of
serum LPS-induced IL-6 and TNF-α correlate with reduced
mRNA levels for these genes, and other related proinflam-
matory genes, in the spleen and liver which are tissues
well-known to express IL1β, IL-6, TNF-α and COX-2.
Additionally, we sought to determine whether differences
in expression levels of each gene existed between the
spleen and liver. These organs contain macrophages and




All chemicals were purchased from Sigma Chemical Co.
(St. Louis, MO) unless otherwise noted. Parthenolide
(Calbiochem, San Diego, CA) was dissolved in tissue cul-
ture grade dimethyl sulfoxide (DMSO). Lipopolysaccha-
ride (LPS) from Salmonella typhimurium [1.5 EU/ng LPS;
Stimulation index (SI) 3.6 @15.6 µg/ml LPS] was dis-
solved in endotoxin-free tissue culture grade water.
Experimental design
All animal handling was conducted in accordance with
guidelines established by the National Institutes of
Health. Experiments were designed to minimize the num-
bers of animals used. Female B6C3F1 mice (8–10 weeks)
were obtained from Charles River (Portage, MI). Animals
were housed 3 or 4 per cage with a 12 h light/dark cycle,
provided standard rodent chow and water ad libitum, and
acclimated to their environment at least one week before
the start of experiments.
Chow and water were removed from cages one hour prior
to the start of each experiment. Mice were co-treated with
5 mg/kg, i.p. (in 50 µl DMSO) parthenolide and 1 mg/kg,
i.p. LPS (in 100 µl water). This parthenolide dose was
selected based on solubility limitations and because it was
the lowest dose to show consistent inhibition of IL-6 and
TNF-α elevation in four preliminary studies using doses at
0.05, 0.5, 1, 5 and 10 mg/kg. Vehicle-treated mice received
50 µl DMSO, i.p. and 100 µl water, i.p. Parthenolide con-
trol animals received parthenolide 5 mg/kg, i.p. and 100
µl water, i.p. After 90 minutes, blood was collected by
retro-orbital bleeding under methoxyflurane anesthesia.
Animals were then immediately euthanized by cervical
dislocation and spleen and liver were collected. The time
interval was chosen based on preliminary studies of LPS
induction in expression of the four target genes. This
euthanasia method was chosen to minimize artifactual
immunologic effects [16] and was approved by MSU All
University Committee on Animal Research and Care.
Serum IL-6, TNF-α, and IL-1β determination by ELISA
Blood was allowed to clot overnight at 4°C. Serum was
analyzed for IL-6, TNF-α and IL-1β by ELISA. IL-6 analysis
was performed using purified and biotin-conjugated rat
anti-mouse IL-6 antibodies from PharMingen (San Diego,Page 2 of 8
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(Sigma) and 3,3',5,5'-tetramethylbenzidine (TMB, Fluka,
Ronkonkoma, NY) were used for detection. Absorbance
was read at 450 nm using a Vmax™ Kinetic Microplate
Reader (Molecular Devices, Menlo Park, CA). For TNF-α
analysis the OptEIA Set: Mouse TNF-α (Mono/Poly) kit
was employed (PharMingen). For IL-1β analysis, a Duo-
Set® ELISA (R&D Systems, Minneapolis, MN) was used.
The sensitivity of all three ELISAs was 20 pg/ml.
Total RNA extraction from spleen and liver
Spleens and livers were cut into small pieces and placed
into TRIzol® Reagent (Invitrogen Life Technologies,
Carlsburg, CA). Samples were homogenized for 30 sec-
onds at setting 8 using a Polytron® Homogenizer (Brink-
mann, Westbury, NY) and RNA extractions were
completed according to manufacturer's instructions. Total
RNA was quantified at 260 nm using a GeneQuant RNA/
DNA Calculator (Pharmacia Biotech, Cambridge,
England).
mRNA quantification from spleen and liver
Relative IL-6, TNF-α, IL-1β and COX-2 mRNA levels were
determined according to manufacturer's instructions
using TaqMan ® real-time reverse transcription (RT)-
polymerase chain reaction (PCR), ABI Prism® 7700
Sequence Detection System (Applied Biosystems, Foster
City, CA) and Applied Biosystems reagents unless indi-
cated otherwise. The RT-PCR reaction was carried out in a
total reaction volume of 25 µl containing: 1) RNase-free
water (Sigma) to 25 µl; 2) 12.5 µl TaqMan® One-Step RT-
PCR Master Mix Reagent; 3) 1.25 µl either IL-6, TNF-α or
IL-1β Pre-Developed Assay Reagent (primer and probe
sets); 4) 1.25 µl 18S rRNA Pre-Developed Assay Reagent;
5) 50 ng total RNA in RNase-free water and 6) 0.63 µl
MultiScribe and RNase Inhibitor Mix. COX-2 mRNA was
similarly analyzed using forward 5'-CAGAAC CGCATT
GCCTCTG-3' and reverse 3'-AGCTGTACTCCTGGTCT-
TCAATGTT-5' primers (900 nM each) (Michigan State
University Genomics Facility, East Lansing, MI) and probe
6FAM-CAACACACTCTATCACTGGCACCCCCTG-TAMRA
(250 nM) designed using Primer Express™ software
(Applera Corporation, Norwalk, CT). All samples were
multiplexed with 18S rRNA which served as an endog-
enous reference for cytokine mRNA normalization. All
samples were assayed in duplicate and serial dilutions of
standard (total RNA from LPS-treated mouse spleen) in
triplicate. No template control and no RT negative control
reactions were also performed. Reaction conditions were:
48°C for 30 min; 95°C for 10 min; and 40 cycles of 95°C
for 10 seconds and 60°C for 1 min.
Statistics
All statistical analyses were performed using SigmaStat
Statistical Analysis Software (Jandel Scientific, San Rafael,
CA). For comparison of two groups, a Student's t-test was
used. For comparisons of multiple groups using paramet-
ric data, one-way analysis of variance (ANOVA) using Stu-
dent-Newman-Keuls Method for all pairwise multiple
comparisons was performed.
Results
Parthenolide co-treatment in vivo inhibits LPS-induced IL-
6 protein production in serum
In order to determine the systemic effect of parthenolide
co-treatment on LPS-induced IL-6 production, mice were
treated with parthenolide (5 mg/kg, i.p.) and LPS (1 mg/
kg, i.p.) for 90 minutes. Blood was collected and serum
analyzed for IL-6. Animals treated with LPS alone pro-
duced 26 ± 2.6 ng/ml of IL-6 (Fig. 1). Serum concentra-
tions of IL-6 were not detectable in vehicle and
parthenolide control animals. Co-treatment with parthe-
nolide caused a 35 percent reduction in LPS-induced IL-6
IL-6 protein production in sera following parthenolide and LPS co-tr atmentFigure 1
IL-6 protein production in sera following parthenolide and 
LPS co-treatment. Female B6C3F1 mice were co-treated with 
parthenolide (5 mg/kg, i.p.) or 50 µl DMSO and LPS (1 mg/kg, 
i.p.) or 100 µl water. After 90 minutes, blood was collected 
and serum analyzed for IL-6 by ELISA. The letter (a) indicates 
a significant difference compared to vehicle and parthenolide 
controls; (b) indicates a significant difference compared to 
LPS. Data are mean ± SEM (n = 16, controls n = 4), and is a 
combination of 4 separate experiments.Page 3 of 8
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(P < 0.05).
Parthenolide co-treatment in vivo impairs LPS-induced IL-
6 mRNA expression in spleen but not liver
Relative IL-6 mRNA expression in the spleen and liver of
co-treated animals was also determined by real-time RT-
PCR. IL-6 mRNA expression was significantly induced in
spleen 239 ± 19-fold spleen control) and liver (117 ± 18-
fold liver control) (Fig. 2). IL-6 expression in vehicle and
parthenolide control animals was negligible in both
spleen and liver samples. Splenic IL-6 mRNA levels of par-
thenolide and LPS co-treated animals (191 ± 12-fold) was
20 percent less than compared to spleens from LPS-only
treated animals (p < 0.05), but not significantly different
in liver (P < 0.05). Overall, IL-6 mRNA expression in
spleen was 2.8-fold higher than the liver in LPS-treated
animals, and was 1.4-fold higher in the spleen of animals
receiving LPS plus parthenolide co-treatment compared to
that of the liver.
Parthenolide co-treatment in vivo does not inhibit LPS-
induced TNF-α protein production in serum
LPS-treated animals exhibited significantly increased TNF-
α concentration (2.50 ± 0.27 ng/ml) in sera compared to
both vehicle and parthenolide control animals (Fig. 3).
TNF-α was not detectable in either control group. TNF-α
concentrations in animals co-treated with parthenolide
plus LPS (2.11 ± 0.26 ng/ml) were not significantly differ-
ent from LPS-only treated animals (P < 0.05) although
there was a downward trend.
Parthenolide co-treatment in vivo does not affect LPS-
induced TNF-α mRNA in spleen and liver
TNF-α mRNA was also increased in the spleen (4.84 ± 1.4-
fold) and liver (2.33 ± 0.71-fold) of LPS-treated animals
over controls. In both the spleen and liver there were no
differences in TNF-α mRNA expression between LPS-
treated and LPS plus parthenolide-treated mice (Fig. 4) (P
< 0.05). In fact, there was no statistical differences among
any of the groups evaluated in this study (P < 0.05). LPS-
induced splenic TNF-α mRNA levels were considerably
higher (14-fold) than those in the liver.
Parthenolide co-treatment in vivo elevates LPS-induced IL-
1β mRNA in spleen but not liver
Serum IL-1β was not detectable in any of the groups
tested. However, IL-1β mRNA expression was significantly
IL-6 mRNA expression levels in spleen and liver following parthenolide and LPS co-tr atmentFigure 2
IL-6 mRNA expression levels in spleen and liver following 
parthenolide and LPS co-treatment. Female B6C3F1 mice 
were co-treated with parthenolide (5 mg/kg, i.p.) or 50 µl 
DMSO and LPS (1 mg/kg, i.p.) or 100 µl water. Spleen and 
liver were collected after 90 minutes and total RNA was 
extracted and subjected to real-time, one-step RT-PCR using 
TaqMan primers and probes. IL-6 mRNA levels were normal-
ized using 18S rRNA and related to spleen control values. (a) 
indicates a significant difference compared to vehicle and par-
thenolide controls; (b) indicates a significant difference com-
pared to LPS. Data are mean ± SEM (n = 16, controls n = 4), 
and is a combination of 4 separate experiments.
TNF-α protein production in sera following parthenolide and LPS co-treatmentFigure 3
TNF-α protein production in sera following parthenolide and 
LPS co-treatment. Mice were treated and sera analyzed for 
TNF-α as described in Fig. 1 legend. The letter (a) indicates a 
significant difference compared to vehicle and parthenolide 
controls. Data are mean ± SEM (n = 16, controls n = 4), and 
is a combination of 4 separate experiments.Page 4 of 8
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7.43-fold) of LPS-only treated animals in comparison to
vehicle and parthenolide control animals (Fig. 5). The
level of IL-1β mRNA in spleen and liver of vehicle and par-
thenolide control animals was negligible. In the spleens of
co-treated animals, there was a significant (p < 0.05)
increase in IL-1β mRNA (21.48 ± 6.91-fold) compared to
LPS-only treated animals. IL-1β mRNA expression was
3.2-fold higher in spleen of LPS-only treated animals, and
4.5-fold higher in LPS plus parthenolide co-treated ani-
mals, when compared to expression levels of the liver.
Parthenolide co-treatment in vivo does not affect LPS-
induced COX-2 mRNA in spleen and liver
Relative COX-2 mRNA expression was assessed in the
spleen and liver of parthenolide plus LPS co-treated ani-
mals. COX-2 mRNA expression was markedly induced in
the spleen of LPS treated animals (44.8 ± 5.0-fold over
control) and increased to a lesser extent in liver (4.6 ± 0.9)
(Fig. 6). In both spleen and liver samples there were no
significant differences in COX-2 mRNA expression
between LPS-treated and LPS plus parthenolide-treated
mice (P < 0.05). Overall, COX-2 mRNA expression levels
were 15.6- and 14.2-fold higher in spleen of LPS-treated
mice and parthenolide plus LPS-treated mice, respec-
tively, when compared to expression levels observed in
liver.
Discussion
Parthenolide has been demonstrated to inhibit inflamma-
tory gene expression in vitro (4–8, 13). The results of this
study are important because it is the first, to our knowl-
edge, to evaluate parthenolide's effect on inflammatory
gene expression in two primary sites of the LPS response –
the spleen and the liver. The data indicate that protein
concentrations in serum followed a similar trend to
splenic mRNA accumulation for IL-6 in LPS and parthe-
nolide/LPS co-treated mice. However protein and splenic
mRNA levels were not consistent with liver samples. The
mRNA levels of each inflammation-related gene in the
liver was not changed, irrespective of parthenolide co-
treatment, when compared to LPS alone.
There is a marked contrast between the robust attenuation
by parthenolide of proinflammatory gene expression
reported in vitro (4–12, 15) and the small responses
reported in animals here and previously (13). It is possi-
ble that in the whole animal the kinetics absorption,
metabolism and distribution and clearance of partheno-
lide preclude sufficient contact time in target immune tis-
sue to evoke potent attenuation of LPS response. These
TNF-α mRNA expression levels in spleen and liver following parthenolide and LPS co-treatmentFigure 4
TNF-α mRNA expression levels in spleen and liver following 
parthenolide and LPS co-treatment. Mice were treated and 
analyzed for TNF-α mRNA described in Fig. 2 legend. TNF-α 
mRNA levels were normalized using 18S rRNA and related 
to spleen control values. Data are mean ± SEM (n = 16, con-
trols n = 4), and is a combination of 4 separate experiments.
IL-1β mRNA expression levels in spleen and liver following parthenolide and LPS co-treatmentFigure 5
IL-1β mRNA expression levels in spleen and liver following 
parthenolide and LPS co-treatment. Mice were treated and 
analyzed for IL-1β mRNA as described in Fig. 2 legend. The 
letter (a) indicates a significant difference compared to vehi-
cle and parthenolide controls; (b) indicates a significant dif-
ference compared to LPS. Data are mean ± SEM (n = 16, 
controls n = 4), and is a combination of 4 separate 
experiments.Page 5 of 8
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late an in vitro effect of an herbal compound to the in vivo
situation.
Serum IL-6, but not TNF-α, was significantly reduced fol-
lowing co-treatment with parthenolide (5 mg/kg, i.p.)
and LPS (1 mg/kg, i.p.) compared to animals receiving
LPS alone. Similarly, IL-6 mRNA concentration in the
spleens of co-treated animals was significantly reduced,
whereas splenic TNF-α mRNA, and COX-2, were not
changed as compared to LPS- treated animals. In contrast,
the level of IL-1β mRNA in the spleen was significantly
elevated in co-treated mice but no effects were observed in
the liver. Serum IL-1β were also evaluated, but levels were
below the limit of detection in all treatment groups (data
not shown). Absence of serum IL-1β might result from
delay in translation/secretion of the protein after tran-
scription, receptor binding or degradation. Regardless of
the cause, comparisons could not be made between pro-
tein production and mRNA expression for IL-1β in this
study.
The observed mRNA expression levels of the proinflam-
matory cytokines and COX-2 might be higher in spleen
than liver because of inherent phagocytic capacities of the
macrophage cell populations within each organ. In the
spleen, macrophages play key roles in phagocytosis, espe-
cially of nonopsonized particles, whereas the macrophage
of the liver, Kupffer cells, play a major role in the removal
of opsonized particles [17]. Soluble LPS injected i.p.,
might not become opsonized since it is not a particulate
and therefore may be preferentially processed in the
spleen rather than liver. This may account, at least in part,
for the increased cytokine and COX-2 gene expression
observed in the spleen when compared to the liver.
Specific cell populations of spleen and liver are likely to
contribute to observed cytokine expression. Hepatocytes,
the parenchyma cells of the liver, account for 60% of total
liver cells and 80% of the liver's volume [18]. The primary
functions of these cells are exocrine and metabolic in
nature. Although they are capable of functioning as anti-
gen-presenting cells in certain situations, they are not pri-
mary mediators of immune regulation in the liver [19].
Other, nonparenchymal cells of the liver include Kupffer
cells, the resident macrophage, and interstitial dendritic
cell types. Both Kupffer and dendritic cells are capable of
producing proinflammatory cytokines. The macrophage
population of liver (10%) is more than three times larger
than the spleen (3%) [20]. However, the opposite is
observed with respect to dendritic cell populations. In the
spleen, the dendritic cell population is approximately ten
times larger compared to liver [20]. It is possible that den-
dritic cells, which are constitutively activated, might
respond more readily to antigen exposure than macro-
phage cell populations, and as a result, express proinflam-
matory cytokines to a greater extent [21]. These and other
cell types including endothelial and epithelial cells might
also contribute differences in spleen and liver mRNA
expression. Future examination of macrophage responses
at other tissue sites and responses of other cell types is
clearly warranted.
Parthenolide's in vitro effects on mediators of inflamma-
tion including cytokines (TNF-α, IL-1β and IL-6) [5,13],
chemokine (IL-8) [15] and lipid mediators (prostagland-
ins [6,7], COX [4,5] and leukotrienes [4]) have been
extensively studied. Recent research has focused on the
role of transcription factor NF-κB [8,10-12]. Notably,
transcriptional regulation of cytokine genes including
TNF-α [22], IL-6 and IL-8 [23] has been strongly linked to
NF-κB activation. Interestingly, parthenolide has been
shown to inhibit expression of each of these cytokines
[5,13], as well as activation of NF-κB [8,10-12] in cell cul-
ture studies. Parthenolide appears to inhibit NF-κB by tar-
geting the IκB (inhibitor of NF-κB) kinase complex [9]
which might inhibit proinflammatory cytokine and
chemokine gene expression. Relative to other transcrip-
tion factors like CCAAT/enhancer binding protein (C/
EBP)β, NF-κB plays a dominant role in regulation of IL-6
expression in other models of inflammation [24].
COX-2 mRNA expression levels in spleen and liver following parthenolide and LPS co-treatmentFigure 6
COX-2 mRNA expression levels in spleen and liver following 
parthenolide and LPS co-treatment. Mice were treated and 
COX-2 mRNAs analyzed as described in Fig. 2 legend. The 
letter (a) indicates a significant difference compared to vehi-
cle and parthenolide controls. Data are mean ± SEM (n = 16, 
controls n = 4), and is a combination of 4 separate 
experiments.Page 6 of 8
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co-treatment on IL-6 production and gene expression, no
inhibitory effect was observed for TNF-α. Although NF-κB
has been implicated in the transcriptional regulation of
TNF-α, the functional concert of NF-κB with other tran-
scription factors such as activator protein (AP)-1 [25] and
C/EBPβ (reviewed by [26]) may override the importance
of NF-κB in LPS-induced TNF-α expression. The dual
pathway of NF-κB and AP-1 has been shown to enhance
production of some proinflammatory cytokines, notably
TNF-α [27]. Parthenolide inhibits NF-κB, but has no effect
on AP-1 [11]. Therefore, the expression of TNF-α may be
compensated for by transcriptional activation by AP-1.
Similar to the effects observed for TNF-α mRNA expres-
sion, there were no significant changes in COX-2 mRNA
expression of LPS versus LPS plus parthenolide co-treated
animals. Hwang et al. [5] demonstrated the inhibitory
effects of parthenolide on LPS-induced COX-2 protein
and mRNA, however, those studies employed cultured
alveolar macrophage cells rather than an in vivo model as
described here. No other studies have directly evaluated
the effect of parthenolide on COX-2 mRNA. The COX-2
gene is regulated by a number of transcription factors
including NF-κB, C/EBPβ and AP-1 as well as cAMP
response element-binding protein (CREB) and others.
Site-directed mutagenesis studies of basal COX-2 expres-
sion in murine lung tumor derived cell lines highlight the
role of C/EBPβ and CREB as major transcriptional regula-
tors of COX-2 [28], whereas NF-κB appeared to have no
role in COX-2 transcriptional regulation using this model.
Thus the lack of inhibitory effect on COX-2 mRNA expres-
sion might be explained, in part, by the limited role of NF-
κB in COX-2 transcriptional regulation.
IL-1β mRNA expression followed a different pattern than
the other two cytokines. IL-6 was decreased and TNF-α
was unchanged, while IL-1β levels were increased follow-
ing co-treatment with LPS and parthenolide. Although IL-
1β is also transcriptionally regulated by NF-κB [22,25]
and C/EBPβ (reviewed by [29]), similar to IL-6 and TNF-
α, it might be differentially regulated in response to LPS.
In support of this hypothesis, in vivo studies by Zhou et
al. [30] show that mRNA levels of IL-1β in the spleen are
not affected under conditions of LPS tolerance whereas
both TNF-α and IL-6 are reduced.
Conclusion
In summary, parthenolide selectively modulated proin-
flammatory cytokine gene expression in vivo. Only one
gene, IL-6, was modestly suppressed which contrasts with
many in vitro studies suggesting anti-inflammatory effects
of this compound. It is possible that the differences in
metabolism and/or distribution of parthenolide could
explain contrasting in vivo and in vitro results. LPS also
exerted greater effects in spleen than liver on expression of
proinflammatory genes. Higher doses of parthenolide
might have greater effects on IL-6 but there are solubility
issues relative to delivery. In addition, the physiological
significance of greater doses would be questionable.
Further study of the effects of parthenolide and other
herbal constituents on inflammatory gene expression
using model animal systems as described here are critical
to evaluating efficacy of such supplements as well as elu-
cidating their mechanisms of action.
List of abbreviations
alpha, α; hour, h; LPS, lipopolysaccharide; TNF, tumor
necrosis factor; IL, interleukin; COX, cyclooxygenase; PG,
prostaglandin; DMSO, dimethyl sulfoxide; CREB, cAMP
response element-binding protein; C/EBPβ, CCAAT/
enhancer binding protein beta; NF-κB, nuclear factor
kappa B
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
ATS participated in study design, carried out experiments,
performed data analysis and drafted the manuscript. JJP
participated in study design and coordination, as well as
editing and revision of the final manuscript.
Acknowledgements
This work was supported by Public Health Service Grants E09521, ES03553 
and DK058833 from the National Institutes for Health. We would like to 
thank H.R. Zhou and A. Thelen for technical advice and Mary Rosner for 
assistance with manuscript preparation. The authors thank Kate Brackney 
and Dan Lampen for assistance with animal experiments.
References
1. Groenewegen WA, Heptinstall S: A comparison of the effects of
an extract of feverfew and parthenolide, a component of
feverfew, on human platelet activity in-vitro.  J Pharm Pharmacol
1990, 42:553-557.
2. Schinella GR, Giner RM, Recio MC, Mordujovich dB, Rios JL, Manez
S: Anti-inflammatory effects of South American Tanacetum
vulgare.  J Pharm Pharmacol 1998, 50:1069-1074.
3. Jain NK, Kulkarni SK: Antinociceptive and anti-inflammatory
effects of Tanacetum parthenium L. extract in mice and rats.
J Ethnopharmacol 1999, 68:251-259.
4. Sumner H, Salan U, Knight DW, Hoult JR: Inhibition of 5-lipoxyge-
nase and cyclooxygenase in leukocytes by feverfew. Involve-
ment of sesquiterpene lactones and other components.
Biochem Pharmacol 1992, 43:2313-2320.
5. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W: Inhibition of
the expression of inducible cyclooxygenase and proinflam-
matory cytokines by sesquiterpene lactones in macrophages
correlates with the inhibition of MAP kinases.  Biochem Biophys
Res Commun 1996, 226:810-8.
6. O'Neill LA, Barrett ML, Lewis GP: Extracts of feverfew inhibit
mitogen-induced human peripheral blood mononuclear cell
proliferation and cytokine mediated responses: a cytotoxic
effect.  Br J Clin Pharmacol 1987, 23:81-83.
7. Pugh WJ, Sambo K: Prostaglandin synthetase inhibitors in
feverfew.  J Pharm Pharmacol 1988, 40:743-745.Page 7 of 8
(page number not for citation purposes)
Journal of Inflammation 2005, 2:6 http://www.journal-inflammation.com/content/2/1/6Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
8. Uchi H, Arrighi JF, Aubry JP, Furue M, Hauser C: The sesquiter-
pene lactone parthenolide inhibits LPS- but not TNF-alpha-
induced maturation of human monocyte-derived dendritic
cells by inhibition of the p38 mitogen-activated protein
kinase pathway.  J Allergy Clin Immunol 2002, 110:269-276.
9. Hehner SP, Hofmann TG, Droge W, Schmitz ML: The antiinflam-
matory sesquiterpene lactone parthenolide inhibits NF-
kappa B by targeting the I kappa B kinase complex.  J Immunol
1999, 163:5617-23.
10. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, Lehmann V, et al.:
Sesquiterpene lactones specifically inhibit activation of NF-
kappa B by preventing the degradation of I kappa B-alpha
and I kappa B-beta.  J Biol Chem 1998, 273:1288-1297.
11. Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M: Sesquiter-
pene lactone containing Mexican Indian medicinal plants and
pure sesquiterpene lactones as potent inhibitors of tran-
scription factor NF-kappaB.  FEBS Lett 1997, 402:85-90.
12. Rungeler P, Castro V, Mora G, Goren N, Vichnewski W, Pahl HL:
Inhibition of transcription factor NF-kappaB by sesquiter-
pene lactones: a proposed molecular mechanism of action.
Bioorg Med Chem 1999, 7:2343-2352.
13. Smolinski AT, Pestka JJ: Modulation of proinflammatory
cytokine production in vitro and in vivo by the herbal constit-
uents apigenin (chamomile), ginsenoside Rb1 (ginseng) and
parthenolide (feverfew).  Food Chem Toxicol 2005, 41:1381-1390.
14. Kang BY, Chung SW, Kim TS: Inhibition of interleukin-12 pro-
duction in lipopolysaccharide-activated mouse macrophages
by parthenolide, a predominant sesquiterpene lactone in
Tanacetum parthenium: involvement of nuclear factor-kap-
paB.  Immunol Lett 2001, 77:159-163.
15. Mazor RL, Menendez IY, Ryan MA, Fiedler MA, Wong HR: Sesquit-
erpene lactones are potent inhibitors of interleukin 8 gene
expression in cultured human respiratory epithelium.
Cytokine 2000, 12:239-45.
16. Howard HL, McLaughlin-Taylor E, Hill RL: The effect of mouse
euthanasia technique on subsequent lymphocyte prolifera-
tion and cell mediated lympholysis assays.  Lab Anim Sci 1990,
40:510-514.
17. Schuurman H, Krajnc-Franken M, Kuper C, van Loveren H, Vos J:
Immune System.  In Fundamentals of Toxicologic Pathology Edited by:
Haschek W, Rousseaux C. San Diego: Academic Press; 1998:233-272. 
18. Popp J, Cattely R: Hepatobiliary System.  In Fundamentals of Toxi-
cologic Pathology Edited by: Haschek W, Rousseaux C. San Diego: Aca-
demic Press; 1998:127-151. 
19. Lau AH, Thomson AW: Dendritic cells and immune regulation
in the liver.  Gut 2003, 52:307-314.
20. Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A, et al.:
APCs in the liver and spleen recruit activated allogeneic
CD8+ T cells to elicit hepatic graft-versus-host disease.  J
Immunol 2002, 169:7111-7118.
21. Banchereau J, Steinman RM: Dendritic cells and the control of
immunity.  Nature 1998, 392:245-252.
22. Mercurio F, Manning AM: Multiple signals converging on NF-
kappaB.  Curr Opin Cell Biol 1999, 11:226-32.
23. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new
discoveries and insights.  Annu Rev Immunol 1996, 14:649-83.
24. Baeuerle PA, Baichwal VR: NF-kappa B as a frequent target for
immunosuppressive and anti-inflammatory molecules.  Adv
Immunol 1997, 65:111-137.
25. Tak PP, Firestein GS: NF-kappaB: a key role in inflammatory
diseases.  J Clin Invest 2001, 107:7-11.
26. Poli V: The role of C/EBP isoforms in the control of inflamma-
tory and native immunity functions.  J Biol Chem 1998,
273:29279-29282.
27. Yokoo T, Kitamura M: Dual regulation of IL-1 beta-mediated
matrix metalloproteinase-9 expression in mesangial cells by
NF-kappa B and AP-1.  Am J Physiol 1996, 270:F123-F130.
28. Wardlaw SA, Zhang N, Belinsky SA: Transcriptional regulation of
basal cyclooxygenase-2 expression in murine lung tumor-
derived cell lines by CCAAT/enhancer-binding protein and
activating transcription factor/cAMP response element-
binding protein.  Mol Pharmacol 2002, 62:326-333.
29. Wedel A, Ziegler-Heitbrock HW: The C/EBP family of transcrip-
tion factors.  Immunobiology 1995, 193:171-85.
30. Zhou HR, Islam Z, Pestka JJ: Kinetics of lipopolysaccharide-
induced transcription factor activation/inactivation and rela-
tion to proinflammatory gene expression in the murine
spleen.  Toxicol Appl Pharmacol 2003, 187:147-161.Page 8 of 8
(page number not for citation purposes)
